| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | paclitaxel | FIMM | pan-cancer | AAC | 0.04 | 0.8 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.0094 | 0.8 |
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | 0.0091 | 0.8 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.8 |